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Burkholderia pseudomallei is resistant to a diverse group of antimicrobials including
third generation cephalosporins whilst quinolones and aminoglycosides have no reliable
effect. As therapeutic options are limited, development of more effective forms of
immunotherapy is vital to avoid a fatal outcome. In an earlier study, we reported
on the B. pseudomallei serine MprA protease, which is relatively stable over a wide
pH and temperature range and digests physiological proteins. The present study was
carried out to evaluate the immunogenicity and protective efficacy of the MprA as a
potential vaccine candidate. In BALB/c mice immunized with recombinant MprA protease
(smBpF4), a significantly high IgG titer was detectable. Isotyping studies revealed that
the smBpF4-specific antibodies produced were predominantly IgG1, proposing that
immunization with smBpF4 triggered a Th2 immune response. Mice were immunized
with smBpF4 and subsequently challenged with B. pseudomallei via the intraperitoneal
route. Whilst control mice succumbed to the infection by day 9, smBpF4-immunized mice
were protected against the lethal challenge and survived beyond 25 days post-infection. In
conclusion, MprA is immunogenic in melioidosis patients whilst also eliciting a strong
immune response upon bacterial challenge in mice and presents itself as a potential
vaccine candidate for the treatment of melioidosis.
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INTRODUCTION
Burkholderia pseudomallei is the Gram negative etiological agent
for melioidosis, a potentially acute fulminating disease in humans
and animals in Southeast Asia and Northern Australia (Cheng
and Currie, 2005; Peacock, 2006). In areas where this bacterium
is endemic, infection by B. pseudomallei has been estimated to
be responsible for 20–30% mortality due to septicaemia and
40% of sepsis-related mortality (Wiersinga et al., 2006). Human
melioidosis presents with an array of clinical symptoms rang-
ing from acute or chronic localized infection involving a single
organ, to fulminant septicaemia in multiple organs and sep-
tic shock (Cheng and Currie, 2005). Current management of
melioidosis involves the full 20-week duration of third generation
cephalosporins therapy. Unfortunately, treating a B. pseudoma-
llei infection is difficult as the bacterium is intrinsically resistant
to many antibiotics and relapse following apparently successful
therapy is well recognized (Cheng and Currie, 2005).
Production of an effective vaccine against B. pseudomallei is
challenging due to the multi-factorial nature of this pathogen.
Various vaccination strategies, including the use of attenuated
stains of B. pseudomallei (Haque et al., 2006), heat-inactivated
bacteria (Sarkar-Tyson et al., 2009), subunit vaccines (Harland
et al., 2007), and DNA vaccines (Chen et al., 2006) have
been extensively explored, but none were able to confer com-
plete protection against the infection. Currently, the use of
protection-eliciting pathogen proteins, for example virulence
factors, is looked upon as an alternative and viable approach
as previously demonstrated with the caseinolytic protease of
Streptococcus pneumoniae (Cao et al., 2009), parasite cysteine pro-
teases (Jorgensen and Buchmann, 2011), cytotoxic serine protease
of Vibrio harveyi (Cheng et al., 2010), outer membrane proteins
ofHaemophilus parasuis (Yuan et al., 2011), and outer membrane
secretin PilQ of Neisseria meningitidis (Haghi et al., 2012).
A common group of virulence factors shared among bacte-
rial pathogens is protease, and protease inhibitors have proven
effective therapeutic agents in treating infectious diseases in ver-
tebrates (Ribeiro-Guimaraes et al., 2007; Serrano-Luna et al.,
2007). For example, in the pathogenic bacterium Enterococcus fae-
calis, both gelatinase and serine protease are required for systemic
infections in mammalian hosts (Engelbert et al., 2004). Similarly,
the extracellular alkaline serine protease produced by the noso-
comial pathogen Stenotrophomonas maltophilia is an important
pathogenicity factor and has been recognized as a potential ther-
apeutic target (Windhorst et al., 2002). The primary function of
proteases in the bacterial kingdom is to provide a source of free
amino acids for bacterial survival and growth, but there is increas-
ing evidence of the role of proteases in bacterial pathogenesis in
creating a niche for colonisation, suppressing host defence mech-
anisms and supporting host dissemination. Furthermore, the
involvement of proteases in antibody degradation or modulation
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of cellular immune responses is also proposed (Jorgensen and
Buchmann, 2011).
Many reports have alluded to the potential role of proteases
in B. pseudomallei pathogenicity. The serine MprA protease has
been implicated as a possible virulence factor (Lee and Liu, 2000)
causing extensive damage to mammalian physiological proteins
involved in circumventing the detrimental effects of bacterial
secreted proteases (Chin et al., 2007). Previously, we identified
an epitope of the B. pseudomallei protease by peptide biopanning
against anti-B. pseudomallei antibodies, whereby selected pep-
tides displayed a conserved motif of serine-methionine-alanine
(S-M-A). This S-M-A motif mimics the catalytic serine and its
flanking amino acids of the B. pseudomallei mprA gene (Chan
and Nathan, 2005). As a potential antigen involved in B. pseudo-
mallei pathogenesis, we further characterized the MprA protein
and demonstrated that the expressed recombinant MprA pro-
tease maintained superior proteolytic activity over a wide pH
(pH5-11) and temperature (4–68◦C) range and partially digested
immunoglobulins A and G, transferrin and myosin (Chin et al.,
2007).
As the MprA protein carried an antibody-binding epitope
and was implicated in proteolysis, we evaluated the potential of
B. pseudomallei MprA protease as a vaccine candidate in a mouse
model. We observed a significant delay in death of the immu-
nized challenged animals indicating that this protease elicited a
protective immune response in mice.
MATERIALS AND METHODS
ETHICS STATEMENT
All animal experiments were performed in accordance with
the Universiti Kebangsaan Malaysia animal ethics guideline and
approved by the Universiti Kebangsaan Malaysia Animal Ethics
Committee (UKMAEC). BALB/c mice (6 weeks old, female) were
obtained from the Animal House Facility, Universiti Kebangsaan
Malaysia. Mice were maintained under specific-pathogen-free
conditions, subjected to a 12 h light/dark cycle and were fed on
a diet of commercial pellets and distilled water ad libitum.
BACTERIAL STRAINS AND PLASMID
B. pseudomallei human isolate (strain D286) was obtained
from the Pathogen Laboratory, School of Biosciences and
Biotechnology, Faculty of Science and Technology, Universiti
Kebangsaan Malaysia. This bacterial strain was isolated from a
patient with clinical manifestation of melioidosis at the Kuala
Lumpur Hospital and previously characterized based on bio-
chemical tests as well as by 16S rRNA sequencing (Lee et al., 2007).
The recombinant MprA protease (BPSS1933) smBpF4 construct
has been previously described (Chin et al., 2007).
BACTERIAL-CELL FREE CULTURE FILTRATE—C. elegans SURVIVAL
ASSAY
B. pseudomallei bacterial cell-free culture filtrate was prepared and
used to treat Caenorhabditis elegans to evaluate nematode killing.
The assay and preparation of the cell-free filtrate was performed
as previously described (Lee et al., 2011) with minor modifica-
tions. In brief, one B. pseudomallei colony was inoculated into
10ml Brain Heart Infusion (BHI) broth and incubated overnight
at 37◦C. Phenylmethylsulfonyl fluoride (PMSF, 10mM) and
ethylenediaminetetraacetic acid (EDTA, 10mM) were added to
the overnight bacterial culture and further incubated at 37◦C for
30min. Subsequently, the mixture was centrifuged at 4000 g for
15min at 4◦C and the supernatant collected and filtered through a
0.22μm pore size syringe membrane filter unit (Millipore, USA).
The supernatant was supplemented with 1ml S-basal medium.
The assay was performed in six-well microtiter plates containing
2ml of the supernatant and S-basal mixture. Thirty age-matched
C. elegans Glp worms (Lee et al., 2011) were transferred into
the conditioned liquidmedium. Heat-killed Escherichia coliOP50
were supplied to prevent starvation. Mortality of the worms was
monitored at 4-h intervals. E. coli OP50 was used in place of
B. pseudomallei as the negative control.
HUMAN SERA SAMPLES
Culture-confirmed melioidosis patients sera (n = 5) from
Malaysia presenting with acute and chronic disease manifesta-
tions and sera samples of patients presenting with Legionella
infection (n = 5) but confirmed B. pseudomallei-culture negative
were provided by the Institute for Medical Research, Malaysia.
Healthy (confirmed HIV-negative) human sera samples (n = 5)
were generously provided by Clinipath Malaysia Sdn. Bhd.
OVER-EXPRESSIONAND PURIFICATION OF MprA PROTEASE, smBpF4
Over-expression and purification of recombinant MprA protease
smBpF4 were performed as previously described (Chin et al.,
2007).
REACTIVITY OF RECOMBINANT PROTEINS TOWARDMELIOIDOSIS
PATIENTS’ SERA
The 96-well microplates were coated with 0.3μg per well of either
heat-killed (80◦C, 1 h) and sonicated (15min) (Vibracell, Sonics
and Materials, USA) B. pseudomallei or recombinant smBpF4
purified protein in coating buffer (0.1M sodium bicarbonate, p.H
8.6) and incubated overnight at 4◦C. The plates were blocked,
washed, then incubated with human sera samples (1:200 dilution)
and incubated at 37◦C for 1 h as previously described (Chin et al.,
2007; Hara et al., 2009). Rabbit anti-human IgG conjugated with
peroxidase (1:10,000 dilution, Sigma-Aldrich, USA) was added
and incubation continued for 1 h at 37◦C. At the end of the incu-
bation, the plates were washed and 50μl ABTS:peroxidase B (1:1;
KPL, USA) was added as substrate. The absorbance was read at
405 nm on an ELISA reader (Dynex MRX, USA).
MOUSE IMMUNIZATION
BALB/c mice (n = 4, 6 weeks old, female) were immunized via
three doses of 100μg of heat-treated (80◦C, 10min) purified
recombinant smBpF4 protein, via the intra-peritoneal (i.p.) route
over 9 weeks as previously described (Hara et al., 2009). The first
dose was administrated in Freund’s complete adjuvant (Pierce
Biotechnologies, USA) on day 0 and 2, boosts were adminis-
trated on days 14 and 28 with an identical dose of antigen
in Freund’s incomplete adjuvant (Pierce Biotechnologies, USA)
(Harlow and Lane, 1988). Control mice (n = 3) were injected
with Phosphate Buffered Saline (PBS) plus adjuvant as per the
above schedule. The sera samples were collected and recovered
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prior to immunization and 1 week after the first and second
booster according to the procedure of Harlow and Lane (1988)
and antibody titres evaluated before the animals were challenged
with B. pseudomallei. The resulting sera were subsequently used
for antibody response analyses and protease neutralization assays
by zymography
ANALYSIS OF ANTIBODY RESPONSE
Mouse antibody titers against recombinant proteins were mea-
sured by ELISA as previously described (Chin et al., 2007; Hara
et al., 2009) with some modifications. Briefly, 96-well plates
were coated overnight with 1 μg of the purified recombinant
protein used for immunization. Wells were blocked with 5%
skimmed milk to prevent nonspecific binding. The plates were
then washed thoroughly with distilled water. Serum samples were
serially diluted two-fold (1:100 to 1:25,600 dilutions) across the
microtiter plate in 5% skimmed milk and incubated for 1 h at
37◦C. Rabbit anti-mouse IgG conjugated with peroxidase (1:4000
dilution, Pierce, USA) was added and incubation continued for
1 h at 37◦C.
For the analysis of specific antibodies, Horseradish Peroxidase
(HRP)-conjugated goat anti-mouse IgG (Promega, USA) (1:2500
dilution); rabbit anti-mouse IgM (μ chain) (1:2500 dilu-
tion), IgG1 (gamma 1) (1:1000 dilution), IgG2a (gamma 2a)
(1:1000 dilution) or IgG2b (gamma 2b) (1:1000 dilution)
(Zymed® Laboratories, USA) was added prior to the addition of
ABTS:peroxidase B (1:1; KPL, USA). The absorbance was read at
405 nm on an ELISA reader (Dynex MRX, USA).
PROTEASE NEUTRALIZATION BY ZYMOGRAPHY
The ability of anti-smBpF4 mice sera antibodies to neutralize
MprA gelatinase activity was tested by zymography as previously
described (Chin et al., 2007). Briefly, 10μg of purified smBpF4
protein was pre-mixed with 30μg of anti-smBpF4 at 37◦C for
1 h. The mixtures were equilibrated to room temperature and
subsequently subjected to zymography.
MOUSE PROTECTION STUDY
For the challenge experiment, smBpF4-immunized and PBS
control mice were challenged with approximately 1 × 106 CFU
B. pseudomalleiD286 administered intraperitoneally 2 weeks after
the second booster and mice were monitored daily for signs
of mortality for 35 days post-challenge as previously described
(Hara et al., 2009; Su et al., 2010).
ENUMERATIONOF VIABLE B. pseudomallei IN THE BLOOD
smBpF4-immunized and challenged mice were tail-bled on days
6, 12, 18, and 25 post-infection. The blood was then plated on
Ashdown agar and colonies were counted after 2 days incubation
at 37
◦
C.
STATISTICAL ANALYSIS
Statistical analysis on human and mice sera reactivity was
performed using the Student’s t-test. Data are expressed as
the mean ± standard deviation. Mortality of immunized vs.
non-immunized groups was analyzed by Kaplan–Meier survival
analysis and survival curves were compared using the Logrank
test. Differences were considered statistically significant at
P = 0.05. All statistical analyses were performed using GraphPad
Prism® version 4.0 (GraphPad Software, USA).
RESULTS
B. pseudomallei PROTEASES ARE IMPLICATED IN C. elegans KILLING
The prevalent view on the mode of action of extracellular pro-
teases toward nematodes is that these proteases participate in
cuticle penetration. To determine if B. pseudomallei proteases
contribute to killing of C. elegans, a combination of serine pro-
tease inhibitors was added to the B. pseudomallei culture to inhibit
the secreted proteases. Zymography was performed and the
results confirmed that the B. pseudomallei cell-free culture filtrate
gelatinase activity was indeed inhibited by 10mM PMSF (serine
protease inhibitor) and 10mM EDTA (Zn2+ dependent metal-
loprotease inhibitor) (data not shown). Survival of the worms
exposed to the laboratory food source E. coli OP50 remained
at almost 100% over the course of the experiment (Figure 1).
Survival of C. elegans exposed to bacterial cell-free culture fil-
trates treated with PMSF and EDTA was monitored over time
and worms were observed to have an extended life span with
a mean time to death (TDmean) of 65.63 ± 3.70 h compared to
worms exposed to B. pseudomallei D286 cell-free culture fil-
trates in the absence of inhibitors (TDmean = 44.49 ± 1.37 h)
[Logrank (Mantel–Cox) test, P < 0.0001] and B. pseudomallei
D286 (TDmean = 31.35 ± 0.91 h) (Figure 1). PMSF is a common
inhibitor of protease hydrolytic activity and mortality of nema-
todes exposed to PMSF-treated culture filtrates was significantly
delayed, indicating that the proteases most likely killed nematodes
through protein hydrolysis and not via the typical ligand–receptor
interaction mechanism as exemplified by the Bt toxin produced
by Bacillus thuringiensis (Beale et al., 2006). The survival assay
validated the importance of B. pseudomallei proteases as virulence
factors in pathogenesis.
RECOMBINANTMprA PROTEASE (smBpF4) IS A PATIENT
SERO-REACTIVE PROTEIN
To further evaluate and study the sero-reactivity of the smBpF4
protease, the full length recombinant 55 kDa smBpF4 protein was
expressed and purified as previously described (Chin et al., 2007).
The expressed smBpF4 protein was subsequently tested against
melioidosis patient sera, legionellosis patient sera and healthy
subject (HIV-negative) sera. ELISA analyses demonstrated that
smBpF4 reacted with the melioidosis sera but not toward the
legionellosis and healthy sera (Figure 2). The results indicated
that the presence of anti-MprA antibodies is specific to melioi-
dosis patients.
RECOMBINANTMprA PROTEIN IS IMMUNOGENIC AND
INDUCES STRONG ANTIBODY RESPONSES
To assess the immunogenicity of the recombinant smBpF4, sera
were collected and pooled from smBpF4-immunized mice prior
to and following B. pseudomallei challenge, and tested for reac-
tivity with purified smBpF4 protease by ELISA. The specific
antibodies against smBpF4 protease were observed in immu-
nized groups over several dilutions screened but not in the pre-
immunized sera (P < 0.001) (Figure 3A). In addition, the ELISA
results (Figure 3B) demonstrated that the anti-smBpF4 also binds
Frontiers in Cellular and Infection Microbiology www.frontiersin.org June 2012 | Volume 2 | Article 85 | 3
Chin et al. MprA as protective antigen
FIGURE 1 | B. pseudomallei proteases contribute toward lethality in
C. elegans. One-day old Glp worms were transferred to individual
B. pseudomallei cell-free culture without (solid line, black triangles) or with
protease inhibitors (PMSF and EDTA) (dashed line, black triangles), E. coli
OP50 (grey line, open squares) and B. pseudomallei cells (solid line,
black squares). The graph shows the mean ± SD of three replicates
(30 worms/replicate) from a representative of two independent
experiments.
FIGURE 2 | Recombinant MprA protease, smBpF4, is sero-reactive.
Reactivity of purified smBpF4 and B. pseudomallei lysate (Bp) with pooled
melioidosis-confirmed, healthy control and legionellosis-confirmed sera.
Significance was determined by Student’s t-test (∗P < 0.05; ∗∗P < 0.01).
to proteins in the B. pseudomallei lysate. To identify the type of
immune response induced, we determined the levels of specific
IgG subclasses (IgG1, IgG2a, and IgG2b) and IgM by ELISA. The
predominant Ig subclass elicited by smBpF4 immunization was
IgG1, followed by IgG2b and to a lesser extent, IgG2a (Figure 3C).
The ratio of IgG2a/IgG1 was 0.817 in smBpF4-immunized mice
(Figure 3C), indicating a Th2-type immune response in mice.
The ELISA results indicate that recombinant MprA protease is
an immunogenic protein able to trigger specific antibodies in the
immunized mice.
To evaluate the ability of the anti-SmBpF4 antibodies to
neutralize the protease, the polyclonal antibodies were reacted
with smBpF4 protease and analyzed by zymography. smBpF4
gelatinase activity was successfully inhibited by anti-smBpF4
(Figure 3D). Our results thus far support the proposal that when
smBpF4 is utilized as an immunogen, antibodies raised against
the recombinant MprA protease should be able to react with and
neutralize proteases secreted during an active infection, hence
preventing the proteolytic digestion of the infected individual’s
key physiological proteins.
ANTIBODIES RAISED AGAINST smBpF4 ELICIT POTENTIAL
PROTECTIVE IMMUNITY IN MICE
To determine if the immune response induced by immuniza-
tion with smBpF4 could confer protection against B. pseudoma-
llei infection, smBpF4 immunized-animals were challenged with
10 × LD50 of B. pseudomallei D286 3 weeks after the second
immunization boost and survival was observed. We had previ-
ously reported that the LD50 of B. pseudomallei D286 was 105
CFU following infection of BALB/c mice via an i.p. route (Hara
et al., 2009). A challenge dose of 10 × LD50 is expected to cause
100% mortality of the infected animals within the observation
period. Thus, any reduction in the number of dead animals or a
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FIGURE 3 | Recombinant MprA protein is immunogenic and induces a
strong antibody response. (A) Screening of smBpF4-specific IgG
(anti-smBpF4) in immunized BALB/c mice. Mice (n = 4) were immunized with
100μg of purified recombinant smBpF4. Sera collected prior to and after
immunization were pooled and levels of anti-smBpF4 were analyzed by
ELISA. The presence of specific antibodies to purified smBpF4 protein (black
circles) was observed in sera from immunized mice but not in pre-immunized
sera (black squares). (B) Interaction and recognition of anti-smBpF4 with
B. pseudomallei lysate by ELISA. Significance was determined by Student’s
t-test (∗∗P < 0.01). (C) Analysis of anti-smBpF4 antibody isotypes in sera
obtained from immunized BALB/c mice by ELISA. Data represent the mean
absorbance (OD405 nm) ± standard deviation. The IgG2a/IgG1 ratio of
smBpF4-immunized mice is 0.817; (D) smBpF4 protease neutralization assay
by zymography.
significant delay in the time taken for all the animals to succumb
to the challenge in immunized mice would indicate the potential
protective efficacy of this recombinant smBpF4 protease.
Mice immunized with smBpF4 (n = 4) demonstrated better
survival rates than control immunized mice (Figure 4A). In the
control group of mice (n = 3) immunized with PBS in adjuvant
and subsequently challenged with B. pseudomallei, one mouse
succumbed on day-2 post challenge, the second on day-6 and
the last mouse died on day-9 with a median survival of 6 days
(Figure 4A). All of the smBpF4-immunized mice (4/4) survived
beyond 25 days post-challenge. However, viable B. pseudomallei
were still detected and the CFU counts increased in the blood of
smBpF4-immunized and challenged mice over the 25 days post-
challenge (Figure 4B). This eventually led to bacteremia in the
smBpF4-immunized and challenged mice, a hallmark of acute
melioidosis. Concomitantly, one mouse died on day-26, the sec-
ond on day-27 and the third on day-30. Thus, recombinant
smBpF4 demonstrated the ability to confer protection against
B. pseudomallei infection where the median survival was pro-
longed by 22.5 days (P = 0.0101) in immunized animals when
compared to the control group. However, immunization with a
single B. pseudomallei immunogen was unable to provide com-
plete protection probably due to the lack of T cell stimulation
(Patel et al., 2011) as well as the fact that B. pseudomallei patho-
genesis is most likely multi-factorial. The challenged surviving
mice also displayed splenomegaly andmultiple abscess formation,
demonstrating incomplete bacterial clearance from the system
(Figure 4C) similar to that previously reported by Breitbach et al.
(2008).
B. pseudomallei can produce different colony morphologies
in vitro and in vivo. These morphotypes are associated with
phenotypes that alter the ability of B. pseudomallei to survive
in adverse environmental conditions, which could have major
implications for the development of therapeutics and vaccines
(Chantratita et al., 2007; Tandhavanant et al., 2010). Interestingly,
we also observed changes in colony morphotypes in the smBpF4-
immunized and challenged mice over the infection period
(Figure 4D). We identified the colony morphotypes observed in
our study using the colony morphotyping scheme reported by
Chantratita et al. (2007). B. pseudomallei D286 used in the chal-
lenge experiment presented a parental type 1 (the “cornflower
head” morphology) colony morphology when cultured in vitro.
Over time, this morphotype switched from parental type 1 to II
(small and rough colonies) or type III (large and smooth colonies)
(Figure 4D). The type III morphotype is reported to have a fitness
disadvantage and lower intracellular replication rates in human
macrophages when compared to parental type 1 morphotype
(Chantratita et al., 2007; Tandhavanant et al., 2010). The switch to
the type III colony morphotype predominantly seen throughout
the infection period is most likely the contributing factor in the
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FIGURE 4 | Survival and assessment of bacterial burden of recombinant
smBpF4-immunized mice against lethal challenge with 1×106 CFU
B. pseudomallei D286 by the i.p. route of infection. (A) Mice were
immunized with smBpF4 (black squares) prior to challenge with
B. pseudomallei D286. All the smBpF4-immunized mice (black squares)
survived up to or beyond 25 days post-infection. All the PBS-treated control
mice (grey circles) died by day-9 post-challenge. (B) Bacterial loads in the
blood of smBpF4-immunized and challenged mice over the 25 days
post-infection before any deaths were recorded. (C) The appearance of
abscesses on the spleen and splenomegaly of smBpF4-immunized
B. pseudomallei challenged mice (32 days post-infection) compared to the
spleen of control mice. (D) Various B. pseudomallei colony morphotypes on
Ashdown’s agar were observed in the smBpF4-immunized and challenged
mice compared to B. pseudomallei D286 grown in vitro. These different
B. pseudomallei colony morphotypes were confirmed by 16S rRNA
sequencing as previously described (Lee et al., 2007).
observed prolonged survival (Figure 4A) and low bacterial counts
(Figure 4B) in smBpF4-immunized and challenged mice relative
to the initial inoculums.
DISCUSSION
Mortality associated with melioidosis remains high because of
the lack of antimicrobial drugs, which could improve the out-
come during the first 48 h after hospital admission (Peacock,
2006). This highlights the need for melioidosis-specific drugs to
be administered immediately upon diagnosis to avoid a fatal out-
come. Prophylactic recombinant B. pseudomallei proteins have
been evaluated as potential candidate vaccines in animal models
of melioidosis. The recombinant B. pseudomallei outer membrane
protein A (OmpA, BPSL2522) (Hara et al., 2009) and Omp85
(BLSL2151) (Su et al., 2010) were shown to induce protective
immunity against melioidosis. Pathogen surface-associated pro-
teins have predominantly been the first pick for evaluation as
potent antigens but recent findings suggest that secreted enzymes
such as proteases may be effective targets as well (Jorgensen and
Buchmann, 2011). Proteases from other pathogens, including
parasites (Pechine et al., 2011) and bacteria (Murthy et al., 2009),
are highly immunogenic and protective in animal models of
infection. Thus, in this study, we extended the investigation to
evaluate the prophylactic properties of recombinant B. pseudoma-
llei serine MprA protease, a proposed virulence factor, which has
been shown to cause extensive damage of mammalian physiolog-
ical proteins although its role in the pathogenesis of melioidosis is
still unclear.
B. pseudomallei MprA is located on Chromosome 2 of the
B. pseudomallei K96243 genome at position 2,695,482–2,696,984.
This protease is highly conserved among the Burkholderia spp.
and subtilisins from other bacteria, particularly at the subtilisin-
like catalytic triad residues (Asp 102, His 57, and Ser 195)
(Lee and Liu, 2000). Our laboratory had previously utilized
anti- B. pseudomallei protease polyclonal antibodies as a tool
to investigate the protease-antibody interaction. We isolated
phage displayed fusion peptides carrying a consensus peptide
sequence, TKSMALSG, which closely resembled part of the
mprA gene active site sequence, 435GTSMATPHVAG445 (Chan
and Nathan, 2005). Homology modeling of the MprA protein
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based on subtilisin demonstrated that the MprA catalytic bind-
ing pocket inclusive of the consensus sequence TKSMALSG could
be the major potential antibody binding epitope (Chan and
Nathan, 2005). Furthermore, we also proposed that B. pseudo-
mallei MprA protease is produced within the bacterial cytosol
as a pre-proenzyme that is subsequently processed utilizing a
mechanism similar to subtilisin to produce the secreted mature
active protease (Chin et al., 2007). The mprA gene is present
in all 68 B. pseudomallei isolates tested by Lee and Liu (2000)
as well as 11 local Malaysia B. pseudomallei animal isolates
(Chin et al., data not shown). Two studies which utilized a
PCR assay targeting the mprA gene of B. pseudomallei reported
100% sensitivity and specificity in detecting the pathogen in
naturally infected dromedary and clinical samples, suggesting
that MprA protease could be a potential drug target upon diag-
nosis of melioidosis (Neubauer et al., 2007; Suppiah et al.,
2010).
Our group recently reported that different isolates of B. pseu-
domallei have divergent ability to kill the soil nematode C. elegans
(Lee et al., 2011), thus providing us with a viable model to iden-
tify and characterize virulent determinants of B. pseudomallei.
In this regard, the virulence of B. pseudomallei proteases toward
C. elegans was assessed by inhibiting the gelatinase activity with
EDTA and PMSF. The prolonged survival of worms exposed to
inhibitor-treated bacterial cell free culture (Figure 1) confirms the
pathogenic role of B. pseudomallei serine proteases in melioidosis.
To follow up on these findings, preliminary characterization of
the recombinant MprA protease as a potential vaccine candidate
in controlling B. pseudomallei infection was initiated in a mouse
model of B. pseudomallei infection. We clearly demonstrated that
smBpF4 protein is immunogenic in mice whereby high levels of
specific neutralizing IgG capable of inhibiting gelatinase activ-
ity were induced (Figure 3D), suggesting that immunization with
MprA protease can potentially induce an appropriate neutral-
izing immune response to protect the B. pseudomallei-infected
individual from the damages inflicted by MprA protease.
A key issue in vaccine development today is the type of
immune response needed to best protect against organisms for
which there are currently no effective vaccines. Most of the
present generation of successful vaccines depends primarily on
generating high antibody titres and many are administered with
the Th2-biasing adjuvant alum. However, natural protection
against many organisms, particularly intracellular bacteria, is
mainly Th1 in nature (Beverley, 2002). B. pseudomallei is an intra-
cellular facultative pathogen that can successfully evade the host
immune system for an extended period of time. This has made
vaccine development for melioidosis difficult and challenging and
has driven researchers to develop a successful anti- B. pseudoma-
llei vaccine that can strongly induce both humoral antibodies and
a cellular-mediated immune response. Animal models of B. pseu-
domallei infection have been used for the development of effective
vaccines; however the level of protection varied depending on
the different vaccine strategies (Brett and Woods, 1996; Atkins
et al., 2002; Engelbert et al., 2004; Chen et al., 2006; Haque et al.,
2006; Hara et al., 2009; Su et al., 2010). For instance, immu-
nization with attenuated B. pseudomallei mutants and active
immunization with B. pseudomallei lipopolysaccharide resulted
in 60 and 50% survival at day-35 post-challenge of immunized
mice, respectively (Nelson et al., 2004; Haque et al., 2006), whilst
immunization with recombinant B. pseudomallei outer mem-
brane protein Omp85 protected 70% of immunized mice up to
14 days (Su et al., 2010). Hence, data from our study is generally
comparable to these previously reported efficacies. We demon-
strated that all mice immunized with smBpF4 protease survived
beyond 25 days of an active B. pseudomallei infection whereas the
non-immunized mice succumbed within 9 days after infection
(Figure 4A). Furthermore, candidate vaccines that achieved par-
tial protection against the disease in mice suggests potential for
human use and reduction in disease severity alone would be pre-
dicted to improve outcome of high mortality rates (Peacock et al.,
2012). B. pseudomallei survival under adverse environmental con-
ditions is likely to be facilitated by phenotypic adaptability and
plasticity (Chantratita et al., 2007). The morphotype III observed
in smBpF4-immunized mice was previously reported to be more
resistant to the antimicrobial peptide LL-37 (Tandhavanant et al.,
2010). This suggests that B. pseudomallei D286 undergoes a phe-
notypic change to adapt, survive, and replicate in the presence
of bactericidal substances within the smBpF4-immunized host
milieu.
The type of immune response induced by a vaccine antigen is
very important for the success of the vaccine (Yuan et al., 2011).
Different IgG subclasses have distinct effector functions. In the
context of vaccination, different antigenic stimuli preferentially
induce different antibodies (Findlow et al., 2006) and different
domains of the same antigen can induce antibodies of different
IgG subclasses (Soininen et al., 1999). In mice, immunoglobulin
isotype switching from IgM to IgG1 is associated with a Th2-type
response, whereas IgG2a is associated with a Th1-type response
and promoted by interferon gamma (Chen et al., 2006; Yuan
et al., 2011). Furthermore, IgG has been shown to be the most
effective IgG subclass antibodies in binding to FcγR1 on phago-
cytic cells (Li et al., 2007). Several studies have demonstrated
that mice with an induced Th1-type immune response showed
greater resistance to B. pseudomallei compared to mice with a
Th2-type immune response (Hoppe et al., 1999; Ulett et al., 2000;
Healey et al., 2005). The antibody subclass analysis of sera from
smBpF4-immunized mice revealed production of both IgG2a and
IgG1, the higher levels of the latter indicate a dominant Th2
response over Th1. Furthermore, induction of a Th2-response
was also noted for the prophylactic properties of the B. pseudo-
mallei recombinant Omp85 protein (Su et al., 2010). Proteases
from parasites (Jorgensen and Buchmann, 2011), Clostridium dif-
ficile (Pechine et al., 2011), V. harveyi (Cheng et al., 2010) and
Vibrio parahaemolyticus (Liu et al., 2011) have also been pro-
posed as promising vaccine candidates able to modulate Th1/Th2
responses in vaccinated animals.
In summary, our study has demonstrated that the B. pseu-
domallei MprA protease is a promising prophylactic candidate
against B. pseudomallei although the protection provided by this
single protein was incomplete. Earlier studies have also noted that
administration of single B. pseudomallei antigens is insufficient
to confer total protection against melioidosis, therefore, a combi-
nation of multiple immunogens should be evaluated for a more
complete anti- B. pseudomallei protection.
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